65,437 trials
Revision Total Hip Arthroplasty · Primary Total Hip Arthroplasty
Primary: Implant Survival: Acetabular Cup Survival at 2-year Follow-up — 94.7; 100 percentage of implants survival
Anemia
Primary: Incidence of Treatment-emergent Adverse Events During Each 7-day Study Period — 174; 114 participants
Actinic Keratosis · Warts · Basal Cell Carcinoma
Primary: Number of Accumulated New Skin Lesions at Month 3 — 65; 103 new skin lesions — p=0.0120
Advanced Adult Hepatocellular Carcinoma · Advanced Fibrolamellar Carcinoma
Primary: Overall Response Rate — 1; 20; 10; 4 Participants
SARS-CoV-2
Primary: Serum Concentrations of AZD7442 — 86.32; 91.88; 92.49; 84.69 Microgram per milliliter (ug/mL)
Effectiveness of Aromatherapy
Primary: Numerical Rating Pain Scale — 5.7; 5.3; -1 score on a scale — p=0.008
Colorectal Cancer
Primary: Intention to Talk to Doctor About Colorectal Cancer Screening — 11.42; 11.31; 11.87; 11.42 units on a scale
Generalized Myasthenia Gravis
Primary: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) — 78.4; 94.1 percentage of participants
HIV/AIDS · Pre-exposure Prophylaxis
Primary: Satisfaction of the Utilization of the CHW to Aid in Accessing PrEP Assessed by the Client Satisfaction Questionnaire-Revised — 29.5 Score on CSQ-8
Gestational Weight Gain
Primary: Total Gestational Weight Gain (GWG) — 10.5; 11.3 kilograms — p=0.014
Diabetes Mellitus, Type 2
Primary: Change in Glycocalyx Integrity-Perfused Boundary Region — -0.0057 micrometers (mcm)
Insomnia · Alcohol Use Disorder
Primary: Insomnia Severity — 17.97; 19.26; 5.69; 10.96 score on a scale
Asthma
Primary: Number of Treatment Emergent Adverse Events — 6; 1; 7 Participants
Locally Advanced Pancreatic Carcinoma(LAPC)
Primary: Disease Control Rate (DCR) — 73 Percentage of participants
Healthy
Primary: Intention to Register — 3.32; 3.06; 4.15; 3.27 score on a scale — p=.001